Herrera Victoria L, Pasion Khristine A, Moran Ann Marie, Zaninello Roberta, Ortu Maria Francesca, Fresu Giovanni, Piras Daniela Antonella, Argiolas Giuseppe, Troffa Chiara, Glorioso Valeria, Masala Wanda, Glorioso Nicola, Ruiz-Opazo Nelson
Whitaker Cardiovascular Institute, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Hypertension and Related Diseases Center, AOU-Universita' di Sassari, Sassari, Sardinia, Italy.
PLoS One. 2015 Jan 23;10(1):e0116724. doi: 10.1371/journal.pone.0116724. eCollection 2015.
Identification of susceptibility genes for essential hypertension in humans has been a challenge due to its multifactorial pathogenesis complicated by gene-gene and gene-environment interactions, developmental programing and sex specific differences. These concurrent features make identification of causal hypertension susceptibility genes with a single approach difficult, thus requiring multiple lines of evidence involving genetic, biochemical and biological experimentation to establish causal functional mutations. Here we report experimental evidence encompassing genetic, biochemical and in vivo modeling that altogether support ATP1A1 as a hypertension susceptibility gene in males in Sardinia, Italy. ATP1A1 encodes the α1Na,K-ATPase isoform, the sole sodium pump in vascular endothelial and renal tubular epithelial cells. DNA-sequencing detected a 12-nucleotide long thymidine (12T) insertion(ins)/deletion(del) polymorphism within a poly-T sequence (38T vs 26T) in the ATP1A1 5'-regulatory region associated with hypertension in a male Sardinian population. The 12T-insertion allele confers decreased susceptibility to hypertension (P = 0.035; OR = 0.50 [0.28-0.93]) accounting for 12.1 mmHg decrease in systolic BP (P = 0.02) and 6.6 mmHg in diastolic BP (P = 0.046). The ATP1A1 promoter containing the 12T-insertion exhibited decreased transcriptional activity in in vitro reporter-assay systems, indicating decreased α1Na,K-ATPase expression with the 12T-insertion, compared with the 12T-deletion ATP1A1 promoter. To test the effects of decreased α1Na,K-ATPase expression on blood pressure, we measured blood pressure by radiotelemetry in three month-old, highly inbred heterozygous knockout ATP1A1+/- male mice with resultant 58% reduction in ATP1A1 protein levels. Male ATP1A1+/- mice showed significantly lower blood pressure (P < 0.03) than age-matched male wild-type littermate controls. Concordantly, lower ATP1A1 expression is expected to lower Na-reabsorption in the kidney thereby decreasing sodium-associated risk for hypertension and sodium-induced endothelial stiffness and dysfunction. Altogether, data support ATP1A1 as a hypertension susceptibility gene in a male Sardinian population, and mandate further investigation of its involvement in hypertension in the general population.
由于原发性高血压的发病机制具有多因素性,且受基因-基因和基因-环境相互作用、发育编程以及性别特异性差异的影响,因此在人类中鉴定其易感基因一直是一项挑战。这些并发特征使得采用单一方法鉴定导致高血压的易感基因变得困难,因此需要涉及遗传、生化和生物学实验的多条证据来确定因果功能突变。在此,我们报告了涵盖遗传、生化和体内建模的实验证据,这些证据共同支持ATP1A1作为意大利撒丁岛男性的高血压易感基因。ATP1A1编码α1Na,K-ATP酶同工型,是血管内皮细胞和肾小管上皮细胞中的唯一钠泵。DNA测序在ATP1A1 5'-调控区域的一个多聚T序列(38T对26T)内检测到一个12个核苷酸长的胸腺嘧啶(12T)插入(ins)/缺失(del)多态性,该多态性与撒丁岛男性人群的高血压相关。12T插入等位基因使高血压易感性降低(P = 0.035;OR = 0.50 [0.28 - 0.93]),收缩压降低12.1 mmHg(P = 0.02),舒张压降低6.6 mmHg(P = 0.046)。在体外报告基因检测系统中,含有12T插入的ATP1A1启动子表现出转录活性降低,表明与12T缺失的ATP1A1启动子相比,12T插入时α1Na,K-ATP酶表达降低。为了测试α1Na,K-ATP酶表达降低对血压的影响,我们通过无线电遥测法测量了三个月大、高度近交的杂合敲除ATP1A1+/-雄性小鼠的血压,结果ATP1A1蛋白水平降低了58%。雄性ATP1A1+/-小鼠的血压显著低于年龄匹配的雄性野生型同窝对照(P < 0.03)。一致地,较低的ATP1A1表达预期会降低肾脏中的钠重吸收,从而降低与钠相关的高血压风险以及钠诱导的内皮僵硬和功能障碍。总之,数据支持ATP1A1作为撒丁岛男性人群的高血压易感基因,并要求进一步研究其在一般人群中与高血压的关系。